Navigation Links
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
Date:6/17/2008

contains statements that are forward looking, including statements related to future clinical development plans for PX-866. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-866. There can be no guarantee that the results of preclinical studies or of early clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a resul
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015 CIRTEC Medical Systems, ... services for complex Class III implantable devices ... to develop a new 35,000 sq. ft. advanced ... has a long history of working with world’s ... breakthrough neurostimulation, heart assistance, drug delivery and smart ...
(Date:4/28/2015)... The Pistoia Alliance, a global, not-for-profit ... lower barriers to innovation in R&D, has announced the ... The Ontologies Mapping project has been set up to ... management in life sciences R&D. The project will see ... tools and services to enable the universal application of ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 According to ... than 450,000 patients receive medical treatment from burn injuries ... of burn injury, extensive formation of scars with subsequent ... burn patients for which there is no adequate treatment. ... prevent normal movement and can cause permanent deformity. ...
(Date:4/28/2015)... April 28, 2015 Reproductive endocrinologist Dr. ... in 7 couples battling infertility in this country, testified on ... Texas as the first state in the nation to consider ... embryos to couples who desire to receive them. , Infertility ... fact that infertility is one of the few medical diseases ...
Breaking Biology Technology:CIRTEC Medical Systems Expands Capacity with New Advanced Manufacturing Facility 2Pistoia Alliance Announces Start of Ontologies Mapping Project 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3
... (Amex: CPD ) posted net sales for the ... $108.3 million, as compared to $35.4,million for the corresponding ... over the first quarter of Fiscal 2008. Pre-tax income ... 2009 as compared to a,pre-tax income of $9.6 million ...
... Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... call on Friday, August 8th at 8:30,AM ET, ... 2008. Insmed intends,to issue its quarterly financial results ... To participate in the live conference call, ...
... 24 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI; OTC: MGIFF), ... that the directors of MIGENIX Inc. have called ... held at 2:00 p.m. (Vancouver,time) on October 31, ... Vancouver,British Columbia. Further details with respect to the ...
Cached Biology Technology:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 7Insmed to Host Second Quarter 2008 Conference Call 2
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... (ret) Dale Meyerrose,Chief Information Officer, Office of the ... and Greg Garcia, Assistant Secretary for,Cybersecurity and Telecommunications, ... the Information Assurance community as the keynote,speaker. ... in the federal IA community has collaborated to,create ...
... this - IV (intravenous) lines in a sorghum ... one way that scientists at,the Texas Agricultural Experiment ... biofuel revolution. In Beaumont, Dr. Lee Tarpley, ... professor of crop physiology, have focused,their research on ...
... PITTSBURGH, September 12, 2007 A double amputee whose ... led to the development of new prosthetic innovations that ... the 13th annual Heinz Award for Technology, the Economy ... the world. Dr. Hugh Herr, 43, ...
Cached Biology News:Herr receives Heinz Award for Technology, the Economy and Employment 2Herr receives Heinz Award for Technology, the Economy and Employment 3Herr receives Heinz Award for Technology, the Economy and Employment 4
...
... The Polymerase gene from Thermus ... expressed in E. coli, then highly ... It is used in the amplification ... PCR. The quality of the Taq ...
Rabbit polyclonal to hnRNP-U...
... is a nonspecific endonuclease that degrades double-and ... hydrolyzing phosphodiester linkages, producing mono and oligonucleotides ... Ambion's RNase-free DNase I is of the ... degrade DNA in the presence of RNA ...
Biology Products: